

List of Figures

- Figure 1. Metabolic Changes in T1DM
- Figure 2. Causes and consequences of Insulin resistance
- Figure 3. Proposed Pathogenesis of Type 2 Diabetes
- Figure 4. Mode of action of insulin on glucose uptake
- Figure 5. Secretion of GLP-1 after meal ingestion and metabolism by DPP-IV enzyme
- Figure 6. Structure of DPP-IV enzyme
- Figure 7. Schematic presentation of the proteins of the DPP family
- Figure 8. Effect of DPP-IV and its inhibition on physiology of incretin system.
- Figure 9. crystal structure of DPP-IV homodimer
- Figure 10. DPP-IV dimer of dimers
- Figure 11. (A) β propeller domain of DPP-IV (B) β propeller domain of DPP-IV rotated 90°
- Figure 12. Active site of DPP-IV with substrate Diprotin A
- Figure 13. Structural features required for selective DPP-IV inhibitor
- Figure 14. Effect of DPP-IV inhibition
- Figure 15. Potent DPP-IV inhibitors under recent development
- Figure 16. Structure of dipeptide substrate recognized by DPP IV enzyme
- Figure 17. Cyclic amide or diketopiperazine formation
- Figure 18. Design strategy of cyanopyrrolidine containing peptidomimetic based DPP-IV inhibitors
- Figure 19. Design strategy of peptidomimetic based DPP-IV inhibitors, devoid of CYP liabilities
- Figure 20. Structures of α -amino acids used as a linker
- Figure 21. Structures of substituted 4-Cyano benzoic acids
- Figure 22. Design strategy of aminomethylpiperidone based DPP-IV inhibitors
- Figure 23. Substituents used for synthesis of aminomethylpiperidone based DPP-IV inhibitors
- Figure 24. cyanopyrrolidine containing peptidomimetic based DPP-IV inhibitors
- Figure 25. *In vivo* antidiabetic activity of **17c**, **17d** and NVP-DPP728 in C57 mice (OGTT)
- Figure 26. *In vivo* antidiabetic activity of **17c** and NVP-DPP728 in db/db mice
- Figure 27. Key interactions of compound **17c** and NVP-DPP728 (Overlay pose) with active sites of DPP-IV enzyme

- Figure 28. Key interactions of compound **17c** and NVP-DPP728 with active sites of DPP-IV enzyme
- Figure 29. Peptidomimetics based DPP-IV inhibitors
- Figure 30. Key interactions of compounds **27a**, **34m** and **Denagliptin** with active sites of DPP-IV enzyme
- Figure 31. Overlay binding pose of compounds **27a**, **34m** and **Denagliptin** with active sites of DPP-IV enzyme
- Figure 32. Aminomethyl-piperidone based DPP-IV inhibitors
- Figure 33. Structures of halo-heterocycles and halo-aromatics **64a-v**
- Figure 34. *In vivo* antidiabetic activity of **68v** and Sitagliptin in C57 mice (OGTT)
- Figure 35. *In vivo* antidiabetic activity of **68v** and Sitagliptin in db/db mice
- Figure 36. Key interactions of compound **68v** and Sitagliptin with active sites of DPP-IV enzyme
- Figure 37. New series development based on lead molecule **68v**

List of Tables

- Table 1. Diagnostic Criteria for Diabetes Mellitus and Prediabetes conditions
- Table 2. Insulin analogues and incretin mimetics
- Table 3. Orally administered antidiabetic agents for T2DM treatment
- Table 4. New therapies under clinical development for the treatment of T2DM
- Table 5. Some natural substrates of DPP-IV
- Table 6. DPP-IV inhibitors in clinic and in active development
- Table 7. *In vitro* DPP-IV inhibitory activity of peptidomimetics **11a-h**, **12a-h** and **16a-h**
- Table 8. *In vitro* DPP-IV inhibitory activity and selectivity of peptidomimetics **17a-d** and **18a-b**
- Table 9. Pharmacokinetic study parameters of **17c**, **17d** and **NVP-DPP728**
- Table 10. *In vitro* DPP-IV inhibitory activity of peptidomimetics **27a-j**
- Table 11. *In vitro* DPP-IV inhibitory activity of peptidomimetics **34a-m**
- Table 12. *In-vitro* DPP-IV inhibitory activity of aminomethyl-piperidones (**68a-v**, **69a-e** & **70a-e**)
- Table 13. Pharmacokinetic study parameters of **68v** and **Sitagliptin**
- Table 14. Short listed lead compounds from all the three series

List of Schemes

- Scheme 1. Synthetic methods for the preparation of title compounds **11a-h** and **12a-h**
- Scheme 2. Synthetic methods for the preparation of title compounds **16a-h**
- Scheme 3. Synthetic methods for the preparation of title compounds **17a-d** and **18a-b**
- Scheme 4. Different conditions for the synthesis of Fmoc protected amino acids
- Scheme 5. Synthetic methods for the preparation of peptidomimetics **27a-j**
- Scheme 6. Synthetic methods for the preparation of peptidomimetics **34a-m**
- Scheme 7. Synthetic methods for the preparation of unnatural amino acid **28**
- Scheme 8. Synthetic methods for the preparation of unnatural amino acid **23i**
- Scheme 9. Synthetic methods for the preparation of unnatural amino acid **23j**
- Scheme 10. Synthetic methods for the preparation of aminomethylpiperidones **68a-v**, **69a-e** and **70a-e**
- Scheme 11. Synthetic method for the preparation of benzaldehyde **51a**
- Scheme 12. Synthetic method for the preparation of halo-heterocycle **64n**
- Scheme 13. Synthetic method for the preparation of halo-heterocycle **64o**
- Scheme 14. Synthetic method for the preparation of halo-heterocycle **64r**
- Scheme 15. Synthetic method for the preparation of halo-heterocycle **64s-t**
- Scheme 16. Synthetic method for the preparation of halo-heterocycle **64u**
- Scheme 17. Synthetic method for the preparation of halo-heterocycle **64v**